Answers are grounded in this paper and cite their sources.
were 0.9702 to 1.1097 and 0.9779 to 1.0993, respectively. All adverse events were mild or moderate, and there were no serious adverse events. The pharmacokinetic properties of solifenacin tartrate were similar to those of solifenacin succinate and met the acceptance criteria for bioequivalence. Both formulations were safe, and no significant difference was observed in the safety assessments of the formulations.
No takes yet. Share an insight, caveat, or question.
Kim et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: